APPROACH TO SCREENING
Shared decision-making — Engage in shared decision-making about prostate cancer screening wth your physician. Although the randomized trials of screening all have important methodological limitations, the best available evidence suggests that screening confers a small absolute benefit for reducing prostate cancer mortality and the risk of developing metastatic disease. However, the potential harms from screening that arise from false-positive tests (eg, prostate biopsy, anxiety, overdiagnosis, and treatment complications) are common. (See 'Benefits and harms of screening' )
Shared decision-making is important because it is not appropriate for clinicians to determine how a patient should weigh these potential outcomes. Patients are encouraged to decide for themselves whether the benefits of screening outweigh the harms. Patients and clinicians should engage in shared decision-making when initially discussing screening as well as during subsequent screening discussions (whether the patient has agreed or declined to be screened in the past) [7,27,31-37].
Online patient decision aids are available at American Cancer Society (ACS), American Society of Clinical Oncology (ASCO), and US Centers for Disease Control and Prevention (CDC).
Source: https://www.uptodate.com/contents/screening-for-prostate-cancer#:~:text=(See%20'Shared%20decision%2Dmaking,age%2065)%20%5B31%5D. Last accessed 08/29/2022